CC
NTLA icon

Centiva Capital’s Intellia Therapeutics NTLA Stock Holding History

Centiva Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,703
Closed -$207K – 1550
2022
Q3 		$207K Buy
+3,703
New +$230K ﹤0.01% 1167
2022
Q2 		– Sell
-2,760
Closed -$201K – 1897
2022
Q1 		$201K Buy
+2,760
New +$234K ﹤0.01% 1292
2021
Q4 		– Sell
-3,708
Closed -$497K – 1439
2021
Q3 		$497K Buy
+3,708
New +$561K 0.03% 610

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Centiva Capital's NTLA Position: Q4 2022 in Review

Centiva Capital sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 3,703 shares — an estimated $207K sold.

Centiva Capital first reported a position in NTLA in Q3 2021 and held it in 3 quarters. The position peaked at $497K in Q3 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

  • Centiva Capital reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Centiva Capital sold 3,703 Intellia Therapeutics shares in Q4 2022, an estimated $207K.
  • Centiva Capital first reported a position in Intellia Therapeutics in Q3 2021 and held it in 3 quarters.
  • Centiva Capital's Intellia Therapeutics position peaked at $497K in Q3 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Centiva Capital's 13F filing for Q4 2022, filed 14 Feb 2023.